Full-Time

Medical Science Liaison

South / Southeast

Updated on 9/3/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$165k - $235k/yr

+ Annual bonus + Long-term incentive/equity award

United States

Remote

Territory covers Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. Territory assignments may change.

PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Veeva
FDA Regulations
CRM

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • An advanced degree is required: PharmD, PhD, or MD in a relevant life sciences, pharmacy, or biomedical field.
  • A minimum of 3 years of MSL or related field-based medical affairs experience in the pharmaceutical or biotechnology industry is required for the Medical Science Liaison level.
  • A minimum of 5 years of MSL or field-based medical affairs experience in the pharmaceutical or biotechnology industry is required for the Senior Medical Science Liaison level.
  • Developing or advanced scientific and clinical knowledge of immunology and inflammation is required, depending on level.
  • The candidate must be able to interpret and communicate clinical and scientific data, including study design, statistical concepts, benefit-risk assessment, subgroup analyses, and safety and efficacy profiles.
  • Working proficiency in customer relationship management platforms, such as Veeva, is required for the Medical Science Liaison level; established proficiency in Veeva CRM and medical affairs field tools is required for the Senior level.
  • Knowledge of medical affairs compliance frameworks, including FDA and EMA regulations, PhRMA guidelines, on-label and off-label scientific exchange, and investigator-initiated study management frameworks, is required.
  • The candidate must be able to operate a motor vehicle safely and successfully, hold a valid United States driver's license, and maintain a driving record compliant with company standards.
  • The position may require travel of 50% or more, including occasional overnight stays.
  • The candidate must be able to work evenings and weekends as needed for physician or patient events, both in person and virtually.
  • Depending on geography, the candidate must be able to manage a multi-state territory with a diverse customer base.
Responsibilities
  • Contribute to development and refinement of medical strategy through field insights and engagement with healthcare professionals, key medical experts, and investigators.
  • Develop and execute territory plans aligned with organizational priorities and data milestones.
  • Develop and manage territory relationships with key medical experts and healthcare professionals in the Immunology and Inflammation therapeutic area, including identifying, mapping, and engaging scientific thought leaders, clinical investigators, and relevant academic centers.
  • Develop tiered segmentation, strategic engagement plans, and longitudinal relationship ownership with healthcare professionals, key medical experts, and investigators.
  • Conduct peer-to-peer scientific exchange by sharing clinical and preclinical data, presenting pipeline updates, and discussing unmet medical needs in a balanced, compliant, and scientifically rigorous manner.
  • Support clinical-trial awareness and site-identification efforts by engaging potential investigators and academic institutions and facilitating discussions supporting site initiation and patient enrollment.
  • Serve as the key scientific resource and face of the sponsor for clinical-site investigators from site start-up through study closeout in collaboration with Clinical Operations.
  • Respond to unsolicited medical-information requests accurately, promptly, and compliantly in partnership with Medical Information.
  • Serve as the field-based scientific resource for healthcare professional, key medical expert, and investigator interactions related to investigator-initiated studies, coordinating with Medical Affairs leadership.
  • Support identification of evidence gaps and contribute to evidence-generation strategies.
  • Synthesize and translate field insights into strategic recommendations for Medical Affairs, Clinical Development, and cross-functional teams, including competitive intelligence, clinical-practice trends, and unmet-need observations.
  • Represent the company at scientific conferences, medical congresses, and advisory-board meetings within the Immunology and Inflammation therapeutic area.
  • Lead and manage strategically defined territory relationships with senior key medical experts, clinical investigators, and academic centers, developing individualized engagement plans aligned with pipeline priorities and medical-affairs objectives.
  • Develop and refine territory strategy based on data milestones, influence mapping, and clinical-development priorities, allocating time and resources to maximize impact.
  • Conduct sophisticated peer-to-peer scientific exchange with senior thought leaders, clinical investigators, and healthcare professionals, including emerging clinical data, benefit-risk considerations, and evolving disease paradigms.
  • Serve as a senior field resource for clinical-trial support, including investigator identification, scientific site engagement, and enrollment-strategy discussions with Clinical Development and Clinical Operations.
  • Own and manage investigator-initiated-study relationships, serve as the primary scientific contact for investigators, facilitate the review process, and maintain scientific engagement with funded sites.
  • Present strategic key medical expert engagement insights and field intelligence to Medical Affairs leadership, Clinical Development, and strategy teams, including recommendations that influence organizational decision-making.
  • Contribute to development of Medical Science Liaison scientific training materials, field tools, and disease-area resources.
  • Represent the company at national and international scientific conferences, advisory boards, and key medical expert forums, including contributing to advisory-board development, agenda design, and outcome synthesis.
Desired Qualifications
  • Post-doctoral training, clinical fellowship, or residency in a relevant discipline is strongly preferred.
  • Experience in immunology, inflammation, or a related therapeutic area is strongly preferred for the Medical Science Liaison level.
  • Clinical-stage biotechnology experience is a plus.
  • Prior involvement in investigator-initiated-study management or clinical-trial support activities is preferred for the Senior Medical Science Liaison level.
  • Experience with digital engagement platforms and virtual scientific exchange is preferred for the Senior Medical Science Liaison level.
  • Experience leveraging artificial-intelligence-driven and omnichannel engagement strategies is desirable for the Senior Medical Science Liaison level.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...